Nanjing Leads Biolabs is a China-based biotechnology company running 8 late-stage cancer trials of LBL-024 and LBL-034 in triple-negative breast cancer, non-small-cell lung cancer and hepatocellular carcinoma.
Nanjing Leads Biolabs, based in Nanjing, China, is a biotechnology company. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials, testing LBL-024 and LBL-034 in triple-negative breast cancer, non-small-cell lung cancer, hepatocellular carcinoma, oesophageal cancer and multiple myeloma. The largest, NCT05170958 (A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumours), plans to enrol 396 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.